[HTML][HTML] Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)

C Trebst, S Jarius, A Berthele, F Paul, S Schippling… - Journal of …, 2014 - Springer
Neuromyelitis optica (NMO, Devic's syndrome), long considered a clinical variant of multiple
sclerosis, is now regarded as a distinct disease entity. Major progress has been made in the …

[HTML][HTML] Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)–revised recommendations of the Neuromyelitis Optica Study …

S Jarius, O Aktas, I Ayzenberg, J Bellmann-Strobl… - Journal of …, 2023 - Springer
The term 'neuromyelitis optica spectrum disorders'(NMOSD) is used as an umbrella term that
refers to aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica (NMO) …

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

International IBD Genetics Consortium (IIBDGC)… - Nature …, 2013 - nature.com
Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …

An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis

P Schmidt, C Gaser, M Arsic, D Buck, A Förschler… - Neuroimage, 2012 - Elsevier
In Multiple Sclerosis (MS), detection of T2-hyperintense white matter (WM) lesions on
magnetic resonance imaging (MRI) has become a crucial criterion for diagnosis and …

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni… - The Lancet, 2018 - thelancet.com
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

[HTML][HTML] Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients

S Jarius, K Ruprecht, B Wildemann, T Kuempfel… - Journal of …, 2012 - Springer
Background The diagnostic and pathophysiological relevance of antibodies to aquaporin-4
(AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been …

The runner's high: opioidergic mechanisms in the human brain

H Boecker, T Sprenger, ME Spilker, G Henriksen… - Cerebral …, 2008 - academic.oup.com
The runner's high describes a euphoric state resulting from long-distance running. The
cerebral neurochemical correlates of exercise-induced mood changes have been barely …

[HTML][HTML] Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder

SJ Pittock, A Berthele, K Fujihara, HJ Kim… - … England Journal of …, 2019 - Mass Medical Soc
Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune,
inflammatory disorder that typically affects the optic nerves and spinal cord. At least two …

Region‐specific encoding of sensory and affective components of pain in the human brain: a positron emission tomography correlation analysis

TR Tölle, T Kaufmann, T Siessmeier… - Annals of neurology …, 1999 - Wiley Online Library
Brain imaging with positron emission tomography has identified some of the principal
cerebral structures of a central network activated by pain. To discover whether the different …

Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses

I Kleiter, A Gahlen, N Borisow, K Fischer… - Annals of …, 2016 - Wiley Online Library
Objective Neuromyelitis optica (NMO) attacks often are severe, are difficult to treat, and
leave residual deficits. Here, we analyzed the frequency, sequence, and efficacy of …